[1]
Marsh JL, Thompson LM. Drosophila in the study of neurodegenerative disease. Neuron 2006; 52: 169-78.
[2]
Chiba S, Numakawa T, Ninomiya M, Yoon HS, Hiroshi K. Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling. Psychopharmacology 2010; 211: 291-301.
[3]
Prasad SN. Neuroprotective effect of geraniol and curcumin in an acrylamide model of neurotoxicity in Drosophila melanogaster: Relevance to neuropathy. J Insect Physiol 2014; 60: 7-16.
[4]
Meng X, Munishkina LA, Fink AL, Uversky VN. Effects of various flavonoids on the-synuclein fibrillation process. Parkinsons Dis 2010; 2010: 1-16.
[5]
Breda C, Giorgini F, Steinert JR. Synapses and α-synuclein signalling in disease. Cogent Biol 2015; 1: 1085295.
[6]
Seidl SE, Santiago JA, Bilyk H, Potashkin JA. The emerging role of nutrition in Parkinson’s disease. Front Aging Neurosci 2014; 6: 36.
[7]
Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997; 388: 839-40.
[8]
Cookson MR. The biochemistry of Parkinson’s disease. Annu Rev Biochem 2005; 74: 29-52.
[9]
Marsh JL, Thompson LM. Drosophila in the study of neurodegenerative disease. Neuron 2006; 52: 169-78.
[10]
Feany MB, Bender WWA. Drosophila model of Parkinson’s disease. Nature 2000; 404: 394-4.
[11]
Guo M. Drosophila as a model to study mitochondrial dysfunction in Parkinson’s disease. Cold Spring Harb Perspect Med 2012; 2: a009944.
[12]
Noor R, Mittal S, Iqbal J. Superoxide dismutase–applications and relevance to human diseases. Med Sci Monit 2002; 8: RA210-5.
[13]
Datla KP, Zbarsky V, Rai D, et al. Short-term supplementation with plant extracts rich in flavonoids protect nigrostriatal dopaminergic neurons in a rat model of Parkinson’s disease. J Am Coll Nutr 2007; 26: 341-9.
[14]
Siddique YH, Fatima A, Jyoti S, et al. Evaluation of the toxic potential of graphene copper nanocomposite (GCNC) in the third instar larvae of transgenic Drosophila melanogaster (hsp70-lacZ)Bg9. PLoS One 2013; 8: e80944.
[15]
Khan S, Jyoti S, Naz F, et al. Effect of L-ascorbic acid on the climbing ability and protein levels in the brain of Drosophila model of Parkinson’s disease. Int J Neurosci 2012; 122: 704-9.
[16]
Sghaier MB, Bhouri W, Neffati A, et al. Chemical investigation of different crude extracts from Teucrium ramosissimum leaves. Correlation with their antigenotoxic and antioxidant properties. Food Chem Toxicol 2011; 49: 191-201.
[17]
Wongsawatkul O, Prachayasittikul S, Isarankura-Na-Ayudhya C, et al. Vasorelaxant and antioxidant activities of Spilanthes acmella Murr. Int J Mol Sci 2008; 9: 2724-4.
[18]
Schlumpf M, Lichtensteiger W, Langemann H, Waser PG, Hefti F. A fluorometric micromethod forthe simultaneous determination of serotonin, noradrenaline and dopamine in milligram amounts of brain tissue. Biochem Pharmacol 1974; 23: 2437-46.
[19]
Palladino MJ, Keegan LP, O’Connell MA, Reenan RA. A-to-I premRNA editing in Drosophila is primarily involved in adult nervous system function and integrity. Cell 2000; 102: 437-49.
[20]
Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007; 27: 3338-46.
[21]
Trojanowski JQ, Lee VMY. Fatal attractions of proteins: A comprehensive hypothetical mechanism underlying Alzheimer’s disease and other neurodegenerative disorders. Ann N Y Acad Sci 2000; 924: 62-7.
[22]
Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 1992; 142: 128-30.
[23]
Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD, Giusti P. α-Synuclein and Parkinson’s disease. FASEB J 2004; 18: 617-26.
[24]
Auluck PK, Chan HE, Trojanowski JQ, Lee VMY, Bonini NM. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science 2002; 295: 865-8.
[25]
Siddique YH, Naz F, Jyoti S, Ali F, Fatima A, Khanam S. Protective effect of Geraniol on the transgenic Drosophila model of Parkinson’s disease. Environ Toxicol Pharmacol 2016; 43: 225-31.
[26]
Siddique YH, Naz F, Jyoti S, Afzal M. Protective effect of apigenin in transgenic Drosophila melanogaster model of parkinson’s disease. Pharmacologyonline 2011; 23: 790-5.
[27]
Musacchio JM. Enzymes involved in the biosynthesis and degradation of catecholamines. Iverson L. Biochem Biogen Amines 2013; pp. 1-35.
[28]
Bayersdorfer F, Voigt A, Schneuwly S, Botella JA. Dopamine-dependent neurodegeneration in Drosophila models of familial and sporadic Parkinson’s disease. Neurobiol Dis 2010; 40: 113-9.
[29]
Kostrzewa RM, Kostrzewa JP, Brus R. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson’s disease. Amino Acids 2002; 23: 57-63.
[30]
Shaltiel-Karyo R, Davidi D, Menuchin Y, et al. A novel, sensitive assay for behavioral defects in Parkinson’s disease model Drosophila. Parkinsons Dis 2012; 2012: 697564.
[31]
Rubin GM, Yandell MD, Wortman JR, et al. Comparative genomics of the eukaryotes. Science 2000; 287: 2204-15.
[32]
Siddique YH, Mujtaba SF, Jyoti S, Naz F. GC-MS analysis of Eucalyptus citriodora leaf extract and its role on the dietary supplementation in transgenic Drosophila model of Parkinson’s disease. Food Chem Toxicol 2013; 55: 29-35.
[33]
Panchal K, Tiwari AK. Drosophila melanogaster “a potential model organism” for identification of pharmacological properties of plants/plant-derived components. Biomed Pharmacother 2017; 89: 1331-45.
[34]
Long J, Gao H, Sun L, Liu J, Zhao-Wilson X. Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson’s disease model. Rejuvenation Res 2009; 12: 321-31.
[35]
Ara G, Afzal M, Jyoti S, Siddique YH. Effect of myricetin on the transgenic Drosophila model of Parkinson’s disease. Bull Fac Pharm Cairo Univ 2017; 55: 259-62.
[36]
Ara G, Afzal M, Jyoti S, Siddique YH. Effect of myricetin on the oxidative stress markers in the brain of transgenic flies expressing human alpha synuclein. Int J Nutr Pharmacol Neurol Dis 2017; 7: 101.
81
5
1